Last reviewed · How we verify
12 months of P2Y12 receptor antagonist
12 months of P2Y12 receptor antagonist is a Small molecule drug developed by Beijing Anzhen Hospital. It is currently FDA-approved.
At a glance
| Generic name | 12 months of P2Y12 receptor antagonist |
|---|---|
| Sponsor | Beijing Anzhen Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study (PHASE4)
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS (PHASE4)
- Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction (PHASE4)
- Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 12 months of P2Y12 receptor antagonist CI brief — competitive landscape report
- 12 months of P2Y12 receptor antagonist updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI
Frequently asked questions about 12 months of P2Y12 receptor antagonist
What is 12 months of P2Y12 receptor antagonist?
12 months of P2Y12 receptor antagonist is a Small molecule drug developed by Beijing Anzhen Hospital.
Who makes 12 months of P2Y12 receptor antagonist?
12 months of P2Y12 receptor antagonist is developed and marketed by Beijing Anzhen Hospital (see full Beijing Anzhen Hospital pipeline at /company/beijing-anzhen-hospital).
What development phase is 12 months of P2Y12 receptor antagonist in?
12 months of P2Y12 receptor antagonist is FDA-approved (marketed).